logo

For the Inventor, By the Inventor

Berwyn, PA, United States of America

Nabil Hanna

This inventor holds 10 USPTO granted patents. Top assignees: Smithkline Beckman Corporation, Smithkline Beecham Corporation. Active years: 1987-1994.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nabil Hanna. Retrieved from https://idiyas.com/inventor/nabil-hanna-y5p4tgw2

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 10

% Patents Active = 100.0

Average Co-Inventor Count = 3.9

ph-index = 7

Forward Citations = 174(Granted Patents)


Location History:

  • Berwyn, PA (US) (1987 - 1992)
  • Solana Beach, CA (US) (1994)

Company Filing History:

goldMedal6 out of 207 
 
Smithkline Beckman Corporation
 patents
silverMedal4 out of 2,198 
 
Smithkline Beecham Corporation
 patents

Years Active: 1987-1994

Loading Chart...
10 patents (USPTO):Explore Patents
1. 5317019 - Inhibition of interleukin-1 and tumor necrosis factor production by (1994-05-31),
2. 5145858 - Pyrrolo [1,2-a] imidazole and imidazo [1,2a] pyridine derivatives and (1992-09-08),
3. 5134150 - Inhibition of the 5-lipoxygenase pathway (1992-07-28),
4. 5002941 - Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their (1991-03-26),
5. 4794114 - Inhibition of interleukin-1 production by monocytes and/or macrophages (1988-12-27),
6. 4780470 - Inhibition of interleukin-1 by monocytes and/or macrophages (1988-10-25),
7. 4778806 - Inhibition of interleukin-1 production by monocytes and/or macrophages (1988-10-18),
8. 4751310 - Inhibition of the 5-lipoxygenase pathway (1988-06-14),
9. 4719218 - Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their (1988-01-12),
10. 4686231 - Inhibition of 5-lipoxygenase products (1987-08-11),

Title: The Innovative Journey of Nabil Hanna

Introduction

Nabil Hanna, a distinguished inventor based in Berwyn, PA, has made significant contributions to the field of pharmaceuticals. With an impressive portfolio of 10 patents, Hanna's work primarily focuses on the development of compounds that play a vital role in inhibiting crucial inflammatory processes.

Latest Patents

Hanna's recent patents include groundbreaking advancements in the inhibition of interleukin-1 and tumor necrosis factor production. Notable inventions in this area include compounds comprising pyridyl and phenyl substituted pyrrolo[1,2-a]imidazole derivatives and pyridyl and phenyl substituted imidazo[1,2-a]pyridine derivatives. These compounds, along with pharmaceutical compositions containing them, have demonstrated potential as 5-lipoxygenase pathway inhibitors, showcasing Hanna's innovative prowess in addressing inflammatory diseases.

Career Highlights

Throughout his career, Nabil Hanna has been associated with prominent companies such as SmithKline Beckman Corporation and SmithKline Beecham Corporation. His experiences in these reputable organizations have undoubtedly contributed to his expertise and success as an inventor in the pharmaceutical industry.

Collaborations

Nabil has collaborated with notable professionals in the field, including Paul E. Bender and Don Edgar Griswold. These partnerships have fostered an environment of innovation and teamwork, allowing for the sharing of knowledge and ideas that propel advancements in pharmaceutical research and product development.

Conclusion

Nabil Hanna's dedication to innovation in pharmaceuticals is exemplified through his numerous patents and significant collaborations. As he continues to explore and develop new therapeutic compounds, Hanna remains an influential figure in the quest for improved health solutions and medical therapies. His work serves as an inspiration to aspiring inventors and a testament to the impact of innovation in the medical field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…